The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to...
genentech-access.com was registered 1 decade 2 years ago. It has a alexa rank of #1,231,066 in the world. It is a domain having .com extension. It is estimated worth of $ 960.00 and have a daily income of around $ 4.00. As no active threats were reported recently, genentech-access.com is SAFE to browse.
Daily Unique Visitors: | 712 |
Daily Pageviews: | 1,424 |
Income Per Day: | $ 4.00 |
Estimated Worth: | $ 960.00 |
Google Indexed Pages: | Not Applicable |
Yahoo Indexed Pages: | Not Applicable |
Bing Indexed Pages: | Not Applicable |
Google Backlinks: | Not Applicable |
Bing Backlinks: | Not Applicable |
Alexa BackLinks: | Not Applicable |
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | Not Applicable |
WOT Trustworthiness: | Very Poor |
WOT Privacy: | Very Poor |
WOT Child Safety: | Very Poor |
Alexa Rank: | 1,231,066 |
PageSpeed Score: | 62 ON 100 |
Domain Authority: | 49 ON 100 |
Bounce Rate: | Not Applicable |
Time On Site: | Not Applicable |
Total Traffic: | No Data |
Direct Traffic: | No Data |
Referral Traffic: | No Data |
Search Traffic: | No Data |
Social Traffic: | No Data |
Mail Traffic: | No Data |
Display Traffic: | No Data |
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy...
Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic.
RITUXAN Patient Assistance Programs. Genentech Access Solutions ® —Connecting patients to RITUXAN. Even if you have health insurance, you might feel concerned about the cost of...
My Patient Solutions ®. My Patient Solutions is an online tool to help you enroll and manage your Genentech Access Solutions service requests. It allows you the flexibility to...
Tumor Lysis Syndrome (TLS): Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, sometimes fatal, can occur within 12-24 hours...
Summary. Genentech, Inc. was founded in 1976 by Robert A. Swanson and Dr. Herbert W. Boyer. The company is primarily based around the field of recombinant DNA technology that...
For a list of sample codes for Cathflo, visit Genentech-Access.com. How do I learn about financial assistance options for my eligible patients? For spoiled product, please...
COMMITTED TO HELPING YOU FIND ASSISTANCE OPTIONS FOR ESBRIET Find out what your insurance covers and where to get extra assistance. Genentech Access Solutions is a program that...
Who is LUCENTIS for? LUCENTIS ® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD), macular edema...
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation. For eligible patients with commercial or public health insurance, LUCENTIS Access...
Introducing PHESGO—a new option that combines PERJETA ® (pertuzumab) and Herceptin ® (trastuzumab) in a single ~ 5 minute injection* With PHESGO, part of your HER2+ breast...
What is XOLAIR? XOLAIR ® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat:. moderate to severe persistent asthma in patients 6 years of age...
Learn about OCREVUS® (ocrelizumab), a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis. See full safety for more information.
You Might Qualify for a Referral to the Genentech Patient Foundation. The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance...
Main website: www.genentech-access.com General inquiries, comments and feedback including technical issues involving the Access Solutions websites can be emailed to...
Find out if you qualify for XOLAIR (omalizumab) for subcutaneous use financial support options that may help you cover the cost of your allergic asthma treatment. See full...
H1 Headings: | 2 | H2 Headings: | 5 |
H3 Headings: | 3 | H4 Headings: | 4 |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | Not Applicable | Total Images: | 13 |
Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Domain Registrar: | SafeNames Ltd. |
---|---|
Registration Date: | 2012-04-27 1 decade 2 years 6 months ago |
Last Modified: | 2018-05-01 6 years 6 months 2 weeks ago |
Host | IP Address | Country | |
---|---|---|---|
dnadns2e.gene.com | 72.34.128.76 | United States | |
dnadns3e.gene.com | 72.34.133.50 | United States | |
dnadns4e.gene.com | 72.34.128.50 | United States |
Host | Type | TTL | Extra |
---|---|---|---|
genentech-access.com | A | 3583 |
IP: 72.34.128.158 |
genentech-access.com | NS | 86400 |
Target: dnadns3e.gene.com |
genentech-access.com | NS | 86400 |
Target: dnadns2e.gene.com |
genentech-access.com | NS | 86400 |
Target: dnadns4e.gene.com |
genentech-access.com | SOA | 3600 |
MNAME: bc-dns-ext-mstr.gene.com RNAME: postmaster.no.email.please Serial: 559733277 Refresh: 3600 Retry: 600 Expire: 2592000 |
genentech-access.com | MX | 3600 |
Priority: 10 Target: smtaextvv01.gene.com |
genentech-access.com | MX | 3600 |
Priority: 10 Target: smtaextrwc01.gene.com |
Home of best-selling Christian author Max Lucado. Author of Anxious for Nothing, 3:16, You'll Get through This, Facing Your Giants, and Unshakeable Hope.
Twitter bootstrap resource site with links to top bootstrap sites
La distribución Deepin ha llamado la atención de muchos usuarios, teniendo mucho repunte exitoso Linux con su nueva versión. Cuenta con nuevas características,
Create or view courses on Google or Ordnance Survey maps